Praluzatamab ravtansine | CD markers inhibitor | Read Reviews & Product Use Citations

Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.

CAS No. 2145115-85-9

Purity & Quality Control

≥99

Choose Selective CD markers Inhibitors

Biological Activity

Description	Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.

References
[1] Boni V, et al. Clin Cancer Res. 2022 May 13;28(10):2020-2029.

References

[1] Boni V, et al. Clin Cancer Res. 2022 May 13;28(10):2020-2029.

Product Details

CAS No.	2145115-85-9
ADC antiody	Praluzatamab
ADC cytotoxin	DM4
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field